PAP
NAMS icon

Persistent Asset Partners’s NewAmsterdam Pharma NAMS Stock Holding History

Persistent Asset Partners’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$247K Buy
+7,284
New +$240K 0.07% 188
2026
Q1 		– Sell
-3,948
Closed -$138K – 428
2025
Q4 		$138K Buy
+3,948
New +$144K 0.06% 250

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Persistent Asset Partners's NAMS Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in NewAmsterdam Pharma (NAMS) in Q2 2026: 7,284 shares worth $247K. The stake represents 0.07% of the portfolio and ranks #188 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in NAMS as recently as Q4 2025.

Persistent Asset Partners first reported a position in NAMS in Q4 2025 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Persistent Asset Partners held 7,284 shares of NewAmsterdam Pharma worth $247K as of Q2 2026.
  • NewAmsterdam Pharma was a new Persistent Asset Partners position in Q2 2026.
  • NewAmsterdam Pharma made up 0.07% of Persistent Asset Partners's portfolio in Q2 2026, its #188 holding.
  • Persistent Asset Partners first reported a position in NewAmsterdam Pharma in Q4 2025 and has held it in 2 quarters since.
  • 195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.